Cargando…

Effects of angiotensin receptor blockers (ARBs) on clinical outcomes of patients with hypertension and COVID-19: A 7-month follow-up cohort study

Introduction: Since the coronavirus disease 2019 (COVID-19) pandemic, the use of angiotensin II receptor blockers (ARBs) in hypertensive patients with COVID-19 has been controversial. Following our previous study, after one year, we intended to extend our sample size and results to investigate the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadadi, Azar, Kazemian, Sina, Shafie, Mahan, Ahmadi, Arezoo, Soleimani, Abbas, Ashraf, Haleh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tabriz University of Medical Sciences 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871165/ https://www.ncbi.nlm.nih.gov/pubmed/36699557 http://dx.doi.org/10.34172/jcvtr.2022.30559

Ejemplares similares

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

COVID-19 in Iran: clinical presentations and outcomes in three different surges of COVID-19 infection
por: Hadadi, Azar, et al.
Publicado: (2022)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

Reciprocal Roles of Angiotensin II and Angiotensin II Receptors Blockade (ARB) in Regulating Cbfa1/RANKL via cAMP Signaling Pathway: Possible Mechanism for Hypertension-Related Osteoporosis and Antagonistic Effect of ARB on Hypertension-Related Osteoporosis
por: Guan, Xiao-Xu, et al.
Publicado: (2011)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

MON-596 Effects of Angiotensin Type 1 Receptor Blockers (ARBs) on the Expression and Secretion of Adiponectin and Leptin in Human White Adipocytes
por: Hattori, Naoki, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey
por: Ibrahim, Sarai L., et al.
Publicado: (2016)

Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
por: Pazoki, Marzieh, et al.
Publicado: (2021)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality of Coronary Artery Bypass Grafting
por: Sharafi, Ahmad, et al.
Publicado: (2013)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions
por: Salim, Hamisha, et al.
Publicado: (2022)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
por: Paranjpe, Rutugandha, et al.
Publicado: (2020)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
por: Ong, Hean Teik, et al.
Publicado: (2013)

Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis
por: Wu, Di, et al.
Publicado: (2020)

Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma
por: Omene, Egiroh E, et al.
Publicado: (2023)

Takotsubo syndrome and COVID‐19: A systematic review
por: Ghasemi, Hoomaan, et al.
Publicado: (2022)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

WCN23-0291 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBs) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Qin, X., et al.
Publicado: (2023)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

Continuing versus withholding angiotensin receptor blocker (ARB)/calcium channel blocker (CCB) combination tablets during perioperative periods in patients undergoing minor surgery: a single-blinded randomized controlled trial
por: Takeuchi, Kazuyo, et al.
Publicado: (2022)

On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone
por: Konoshita, Tadashi, et al.
Publicado: (2016)

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
por: Kelleni, Mina T.
Publicado: (2020)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study: ACEI/ARB and vascular calcification
por: Takaori, Kaori, et al.
Publicado: (2021)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension
por: van Sloten, Thomas T, et al.
Publicado: (2022)

The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”
por: Mozafar, Mehrdad, et al.
Publicado: (2022)

Long-Term Impact of the COVID-19 Associated AKI: The Relationship between Kidney Recovery and Mortality in a 10-Month Follow-Up Cohort Study
por: Hadadi, Azar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_80ap7d716a6tlb79vrd3cr6f6a